Pilot healthcare economics and observational study of the OneDose ReadyfusOR (a factory-filled infusion device delivering a continuous infusion of ropivacaine 2mg/ml for up to 48 hours), for the treatment of post-operative pain in patients who have undergone open intra-abdominal surgery (laparotomy)
A Double Blind, Multi-center, Randomized, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Ropivacaine 0.2% Pre-Filled Dispenser for the Treatment of Postsurgical Pain in Patients Undergoing Cesarean Delivery
This study evaluates a Ropivacaine 0.2% Pre-Filled Dispenser in the treatment of post-surgical pain in patients undergoing Cesarean delivery. Half of the patients will receive Ropivicaine and half will receive placebo.
100 项与 BioQ Pharma, Inc. 相关的临床结果
0 项与 BioQ Pharma, Inc. 相关的专利(医药)
100 项与 BioQ Pharma, Inc. 相关的药物交易
100 项与 BioQ Pharma, Inc. 相关的转化医学